Sam Waksal

Sam Waksal is a former biotechnology executive and founder of ImClone Systems, a biopharmaceutical company known for developing cancer treatment drugs. He gained widespread notoriety in 2002 when he was involved in an insider trading scandal that also implicated lifestyle entrepreneur Martha Stewart. As ImClone's CEO, Waksal led the development of Erbitux, an antibody-based cancer drug that eventually gained FDA approval in 2004. His early career included positions as a research fellow at Stanford University and a professor at Mount Sinai School of Medicine, where he specialized in immunology. The insider trading case resulted in Waksal's conviction and a seven-year prison sentence, along with significant fines and restrictions on leading public companies. After his release in 2009, he founded Kadmon Pharmaceuticals, though he later stepped down from leadership positions due to regulatory restrictions. Despite the controversy surrounding his career, Waksal's work in biotechnology contributed to important developments in cancer treatment research. The drug Erbitux continues to be used in treating certain types of cancer, particularly colorectal cancer and head and neck cancer.

Readers focus primarily on news articles and business case studies about Waksal rather than books authored by him, as he has not published major works. Commentary centers on his role in the ImClone scandal and subsequent business ventures. What readers discuss positively: - His scientific background and contributions to cancer drug development - Business acumen in building biotech companies from scratch - The eventual success of Erbitux in cancer treatment Common criticisms: - Unethical behavior and insider trading - Betrayal of shareholders' trust - Impact of scandal on biotech industry reputation Online mentions and discussions appear mainly in: - Business ethics course materials - Financial news archives - Legal case studies - Academic papers on corporate governance No ratings or reviews exist on major book platforms like Goodreads or Amazon, as Waksal is not primarily an author. His story is referenced in books by other writers covering business scandals and pharmaceutical industry history.

Science on Trial: The Whistleblower and the Insider Trading Scandal That Rocked Big Pharma (2024) A first-hand account of Waksal's experiences as founder of ImClone Systems, his involvement in an insider trading scandal, and subsequent imprisonment.

Michael Lewis writes narratives about business scandals and financial misconduct in corporate America. His books like Liar's Poker and Flash Boys expose improprieties in Wall Street culture similar to Waksal's ImClone case.

James B. Stewart investigates corporate fraud and insider trading through detailed reporting of executive misdeeds. His book Den of Thieves covers Wall Street corruption and the actions of executives who abused their positions.

Kurt Eichenwald documents high-profile business scandals through investigative journalism focused on corporate crime. His works like The Informant and Conspiracy of Fools examine executive misconduct and financial fraud.

Charles Gasparino reports on Wall Street culture and financial industry wrongdoing through first-hand sources. His coverage includes executive misbehavior and regulatory failures in the banking sector.

Andrew Ross Sorkin chronicles major business stories with focus on executive decision-making and corporate dealmaking. His book Too Big To Fail examines leadership during financial crises through interviews with key players.